Prostate cancer: Radium-223 safe in combination

Comment

Clemens Thoma. Nat Rev Urol. 2016 Oct.

. 2016 Oct;13(10):563.

doi: 10.1038/nrurol.2016.156. Epub 2016 Aug 17.

No abstract available

Comment on

Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ, Casimiro S, Costa L. Body JJ, et al. Nat Rev Urol. 2015 Jun;12(6):340-56. doi: 10.1038/nrurol.2015.90. Epub 2015 May 5. Nat Rev Urol. 2015. PMID: 26119830 Review.
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators. Saad F, et al. Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26. Lancet Oncol. 2016. PMID: 27473888 Clinical Trial.